In this article, we will list the 5 High Growth Stocks Insiders Are Buying. Please visit 10 High Growth Stocks Insiders Are Buying if you would like to see the extended list and the methodology behind it.
5. Alpha Cognition Inc. Common Stock (NASDAQ:ACOG)
On July 10, 2026, Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition Inc. (NASDAQ:ACOG) with an Outperform rating and $20 price target. Deschner noted that Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine indicated for the treatment of mild-to-moderate dementia in patients with Alzheimer’s disease.
Deschner said Zunveyl is designed to address a large unmet need in Alzheimer’s disease, including gastrointestinal tolerability and other adverse events that are a primary source of discontinuation for the most commonly prescribed class of Alzheimer’s disease drugs, acetylcholinesterase inhibitors.
On June 24, Alpha Cognition Inc. (NASDAQ:ACOG) announced changes to its Board of Directors. Robert Wills was elected Chairman of the Board, succeeding Len Mertz, who retired from the Board.
On June 16, Alpha Cognition announced enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The study is expected to enroll approximately 150 patients across multiple clinical sites and monitor adverse events, treatment persistence, and discontinuation rates.
Alpha Cognition Inc. (NASDAQ:ACOG) develops treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
4. Neuronetics, Inc. (NASDAQ:STIM)
On July 6, 2026, Neuronetics, Inc. (NASDAQ:STIM) announced that management will participate at B. Riley Securities’ Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in person at the InterContinental Boston. Neuronetics will participate in a panel discussion titled “Commercializing the Next Wave of Novel Neuropsychiatric Drugs” alongside Compass Pathways on Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day.
On June 2, Neuronetics announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society Annual Meeting. The company said real-world data from its proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on transcranial magnetic stimulation for mental health conditions. Chief Technology Officer Cory Anderson said the expansion of real-world evidence is “critical” to advancing the understanding of TMS and its role in clinical practice.
Also on June 2, Neuronetics announced that Robert Greene was appointed Senior Vice President of Sales, effective June 1, 2026. Greene brings experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service.
Neuronetics, Inc. (NASDAQ:STIM) provides in-office treatments for patients with neurohealth disorders in the United States and internationally.
3. Empery Digital Inc. (NASDAQ:EMPD)
On July 7, 2026, Empery Digital Inc. (NASDAQ:EMPD) announced that its Board of Directors approved an amendment to the company’s stockholder rights plan to accelerate the expiration date to the close of business on July 6, 2026. The rights plan had been scheduled to expire on February 2, 2027. The Board determined that maintaining the rights plan was “no longer necessary” at this time to serve the best interests of all stockholders.
On July 1, Empery Digital provided additional information on the capital needs tied to its investment in a Midwest facility to be converted into a state-of-the-art AI data center. The company said its funding obligations are limited to the $65M required to close its 25% ownership in the private entity acquiring the facility. Under the terms of the non-binding LOI, the data center build-out costs, power usage, and operating costs will be funded solely by the potential tenant. Empery Digital said it has the capital required to fund the $65M investment from its balance sheet and does not intend to issue equity at or near current share price levels.
On June 30, Empery Digital announced that it entered into a definitive agreement for a $65M investment representing a 25% ownership stake in a private entity acquiring the Midwest facility. The facility has operated as a power-intensive industrial facility for the past three years and includes an owned substation and associated infrastructure for approximately 150 MW of currently available capacity under an existing power agreement with the local utility. A recent load study confirmed the facility’s ability to almost double available power to approximately 300 MW for AI workloads.
Empery Digital Inc. (NASDAQ:EMPD) engages in the digital asset treasury business in the United States.
2. Kalaris Therapeutics, Inc. (NASDAQ:KLRS)
On July 6, 2026, Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In connection with Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board.
David Hallal, Chairman of the Kalaris Board of Directors, said Keating brings strategic, operational, and legal expertise across multiple therapeutic areas and development stages. Hallal also thanked Jovan-Embiricos for her service over the past year, noting her role in helping Kalaris advance TH103 and evolve as a public biotech company.
On June 15, 2026, TD Cowen analyst Tara Bancroft initiated coverage of Kalaris Therapeutics with a Buy rating and no price target. Bancroft said the company’s TH103 is a “differentiated” anti-VEGF by design through more potent VEGF inhibition and retinal retention. Bancroft added that early data in wet age-related macular degeneration suggest even a single dose can achieve competitive efficacy versus the standard of care.
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) develops and commercializes treatments for prevalent retinal diseases.
1. International Flavors & Fragrances Inc. (NYSE:IFF)
On July 1, 2026, Morgan Stanley raised the firm’s price target on International Flavors & Fragrances Inc. (NYSE:IFF) to $95 from $93 and kept an Overweight rating on the shares. The firm cited adjusted estimates and higher peer multiples.
On June 30, Argus raised the firm’s price target on IFF to $85 from $80 and kept a Buy rating on the shares. Argus said that following recent underperformance, the shares are trading near the low end of their historical valuation range. The firm also said IFF’s volume growth and productivity gains can drive sustained earnings growth.
Also on June 30, IFF announced the launch of SENSORA, its advanced patent-pending pro-fragrance technology for home, fabric, and personal care applications. The company said SENSORA is designed to meet demand for a longer-lasting and more sophisticated scent experience by delivering an evolving olfactive profile with sustained release.
International Flavors & Fragrances Inc. (NYSE:IFF) manufactures and markets food, beverage, health and biosciences, scent, and complementary adjacent products in the United States and internationally.
While we acknowledge the potential of IFF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IFF and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
